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Oligonucleotide microarray technology has created a small revolution in the transplant community 
because it has helped to decipher previously unknown molecular processes involved in allograft 
pathology, redefined molecular patterns of diseases that are indistinguishable at the pathological 
level and made possible the definition of new prognostic factors for long-term graft outcomes. 
However, given the tremendous complexity of the biological processes that are involved in the 
pathology of a transplanted organ, the interpretation of transcriptomic data can be speculative 
and oversimplified. Here, we discuss critical considerations regarding the nature of the object 
studied by cDNA microarray technology, the means by which it is observed, the interpretation 
of the observations, and whether the observations make sense in the context of transplant-
related scientific questions. Given these limitations, we believe that global approaches based 
on more functional biological intermediates are necessary for a better understanding of the 
molecular processes that regulate the physiopathology of the transplanted organ.
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elementary questions arise: What is the object we are studying? 
How do we observe it? How do we interpret our observations? Do 
our observations make sense?
These simple questions are important because interpreting 
transcriptomic data without considering the real functional sig-
nificance of the mRNA transcripts (which are biological interme-
diates and not directly involved in functional cellular processes) 
is inherently speculative and oversimplified given the tremen-
dous complexity of the biological processes that are involved in 
the pathology of a transplanted organ. We believe that global 
approaches based on more functional biological intermediates 
are necessary to better understand the molecular processes that 
regulate the physiopathology of a transplanted organ.
Functional interpretation oF mrna expression
the inFormative value oF mrna
The biological process examined by oligonucleotide microarray 
technology is mRNA expression. mRNAs carry genomic informa-
tion that will eventually be translated into a protein, whose func-
tion will depend on complex post-translational modifications. 
Consequently, the simple equation, “mRNA = function,” e.g., trans-
forming growth factor β (TGF-β) mRNA overexpression means 
“fibrosis,” is probably overly speculative. A biological function 
results from the integration of numerous contradictory processes 
that constitute the “interactome,” and therefore, the expression 
level of an mRNA is not necessarily informative of an ongoing 
biological process.
introduction
Kidney allograft damage is often diagnosed too late, after irrevers-
ible tissue injury has been definitively established. A better molecu-
lar characterization of allograft injuries is needed to better prevent 
tissue remodeling. The reversibility of a lesion, independent of its 
origin, is closely related to early diagnosis, and such a diagnosis 
depends on the ability to detect changes in the inner workings of 
cells, i.e., at a molecular level.
Oligonucleotide microarray technology has had a tremendous 
success and has become a standard tool in molecular biology. This 
technology has created a small revolution in the transplant commu-
nity. The application of microarrays to transplantation research has 
revealed previously unknown molecular processes involved in allo-
graft pathology, including tissue responses to immunosuppressive 
drugs (Pallet et al., 2008; Dell’Oglio et al., 2010); redefined molecu-
lar disease patterns that are indistinguishable at the pathological 
level due to the heterogeneity of allograft rejection (Sarwal et al., 
2003); and made possible the definition of new prognostic factors 
for long-term graft outcomes (Einecke et al., 2010). However, to 
date, these functional genomic tools have played an undefined role 
in clinical kidney transplantation diagnostics.
Transcriptomic analysis using oligonucleotide microarray 
technology relies on the observation of the state of a biological 
process, namely transcriptional regulation of genetic information, 
at a given time (the transcriptome). Technological platforms (the 
microarrays) generate huge amounts of data that are managed by 
sophisticated bioinformatics tools. From this basic description, 
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Protein activation catalytic cascades, such as complement, coag-
ulation, and caspase activation, are not regulated at the transcrip-
tional level. For example, the transcriptome does not reflect the 
activation of complement during thrombotic microangiopathies 
or humoral rejection. Cell death processes (i.e., necrosis, apoptosis, 
and autophagy), which are present in an engrafted organ, (Galluzzi 
et al., 2012) may not involve the active expression of genes. Indeed, 
the effective activation and the execution of programmed cell death 
involve catalytic reactions (e.g., caspases activation during apop-
tosis), vesicle trafficking and fusion (in the case of autophagy), or 
signal transduction, kinases activation, and membrane permeabili-
zation in the case of necrosis. Consequently, oligonucleotide micro-
array is not a useful tool to monitor cell death because there is no 
gene or cluster of genes whose expression is specifically attributed 
to a type of programmed cell death (Klionsky et al., 2008; Kepp 
et al., 2011). However, the basal expression of some genes encod-
ing important regulators of programmed cell death is essential for 
the correct execution of programmed cell death sub-routines. This 
is exemplified by the dramatic phenotypic consequences of small 
RNA interference screens (Hitomi et al., 2008).
Transcriptional activity is not a key regulator of fibrogenesis. In 
addition to transcription, a central step in the induction of TGF-β 
is its activation from a reservoir of latent protein complexes in 
the extracellular matrix (Schnaper et al., 2009). TGF-β is basally 
secreted in the microenvironment and aggregates in its latent form 
with proteins in the extracellular matrix. Another important con-
tributor to tissue fibrosis, connective tissue growth factor (CTGF), 
is released in a caspase 3-dependent manner independent of tran-
scription (Laplante et al., 2010).
Non-conventional intercellular communications through mem-
brane vesicles, which play a role in the modulation of alloimmunity 
(Thery et al., 2009), are non-transcriptional processes. Other fun-
damental biological processes that escape transcriptional regula-
tion include protein degradation pathways (e.g., autophagy and 
the proteasome); kinase cascades; and the phosphoproteome; the 
ubiquitin system, which regulates HIF1-α and NF-κB signaling; 
mTOR and the integrated stress response that regulates transduc-
tional activity in response to ischemia (Bando et al., 2004); and 
intracellular vacuolar trafficking, which leads to MHC-peptide 
maturation and presentation.
In conclusion, this list of examples highlights the fact that the 
transcriptome represents only the tip of the iceberg and cannot 
detect a large number of fundamentally important biological path-
ways. Thus, reducing the tissular and cellular response to injury to 
the expression of transcripts can lead to biased and oversimplified 
conclusions.
Emerging methods could help to monitor mRNA actively trans-
lated in the cell (Zanetti et al., 2005; Halbeisen and Gerber, 2009; 
Halbeisen et al., 2009; Mustroph et al., 2009). In this regard, the 
translatome refers to the pool of all RNAs that are associated with 
ribosomes purified via an affinity tag that can be subsequently ana-
lyzed by microarray, and further compared with the transcriptome. 
As an example, the comparison of the relative changes of trans-
latome and global transcript levels in response to stress that arrest 
cell growth correlate well with those in the translatome. However, 
this correlation is generally lost under more mild stresses that do 
not affect cell growth (Halbeisen and Gerber, 2009).
The overexpression of a given mRNA or cluster of mRNAs may 
be interpreted as an indication of the presence of a specific type of 
cell if the mRNA or cluster of mRNAs are assumed to be representa-
tive of the cell type. However, cells often express genes that are not 
usually associated with their lineage, e.g., epithelial cells express a 
wide array of proinflammatory (Bonventre and Zuk, 2004) and 
mesenchymal genes (Hertig et al., 2006), and immune cells express 
endothelial markers (Ma et al., 2010). Conversely, not all cells from 
the same lineage in the biological milieu express a so called “cell-
type marker” (Zeisberg and Duffield, 2010). The great difficulty 
in defining specific cell markers at the protein level also applies to 
mRNAs, and one must be careful when interpreting the expression 
of a transcript as an indication of the presence of a given cell type.
expression kinetics
Transcriptomic analysis provides a global picture of a system at a 
given time and does not reflect the notion of flux, even if a short 
time course is performed. Flux refers to the integration of the pro-
duction, accumulation and degradation of mRNAs. Thus, a given 
expression level per se is not indicative of the ongoing process that 
results in an increase or decrease in the transcript’s expression. The 
mRNA expression level does not reveal the nature of the process 
driving the increase or decrease in mRNA expression. For exam-
ple, mRNAs are degraded during cellular stress by mRNA decay 
(Hollien et al., 2009). This process affects mRNA expression level 
at a given time in the same manner as a repressor that affects the 
transcription rate. However, the biological meaning and implica-
tions of mRNA decay and repressor activation are fundamentally 
different and are not captured by a single-shot microarray analysis.
Emerging techniques address kinetics of RNA production, 
whose application in transplant-related diseases could provide 
additional information on pathophysiological processes not 
monitored by  conventional transcriptomic analysis. These include 
the use of transcripts from nuclei (Barthelson et al., 2007; Zhang 
et al., 2008; Underwood et al., 2010; Yunger et al., 2010), which, 
for example, allow the visualization and analysis of mammalian 
mRNA transcriptional kinetics of single alleles in real time, or 
allow to simultaneously mapping single-stranded RNA regions in 
multiple non-coding RNAs with known structure. Another emerg-
ing method for the assessment of RNA kinetics is the dynamic 
transcriptome analysis (DTA). DTA is a non-perturbing method 
to measure mRNA synthesis and decay rates (Miller et al., 2011; 
Rabani et al., 2011). DTA involves genetically facilitated cellular 
uptake of the nucleoside analogs, metabolic RNA labeling, separa-
tion, and microarray analysis of RNA fractions. This is exempli-
fied by analysis of the osmotic stress response, a conserved stress 
response pathway and one of the best-studied gene-regulatory 
systems in yeast (Miller et al., 2011).
non-transcriptionally regulated biological 
processes
Although each mRNA is translated into a protein at the basal level, 
transcriptional regulation represents just one of the many processes 
involved in the cellular response to environmental changes. Many 
fundamental biological processes implicated in transplantation 
are not transcriptionally regulated, meaning that they will not be 
detected by mRNA expression analysis.
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to speculate. But in retrospect, it is possible that we have tended 
to overestimate their actual contribution to the understanding of 
disease processes in transplantation.
There are two major applications of transcriptomic data analysis. 
The first involves the definition of gene-expression profiles that can 
define a molecular signature of tissular injuries and that define sub-
groups of clinical situations that are undetectable by standard tools. 
As previously noted, such alterations of the expression of transcript 
clusters represent only a small component of the whole biological 
response to injury. Therefore, by using this application, we risk 
overestimating the informational value of studying transcription 
alone, which is partially disconnected from the final function we 
tend to assign.
The most exciting application of microarray analysis is to help 
identify novel biological pathways involved in a particular patho-
logical or physiological setting, which must then be validated 
by cellular and molecular biology studies. These kinds of global 
approaches in the absence of an a priori hypothesis should raise 
additional questions and hypotheses. Such studies constitute the 
first step of mechanistic studies leading to a better understanding 
of the biological processes in which transcripts detected by tran-
scriptomic studies may be implicated. Further characterization of 
such processes will lead to the definition of novel biomarkers and 
potential therapeutic targets. Because mRNAs are biological inter-
mediates, one should not overestimate their significance, especially 
in cases of “data mining.”
Transcriptomic profiling is being replaced by the applications of 
next generation sequencing (NGS). Applications of NGS in trans-
plantation have not been published yet. NGS technologies constitute 
various strategies that rely on a combination of template prepara-
tion, sequencing and imaging, and genome alignment and assem-
bly methods (Metzker, 2010). The increasing feasibility of whole 
genome and whole-exome sequencing (Choi et al., 2009; Cirulli 
et al., 2010), due to increased speed of “next generation” sequenc-
ers, and decreased cost may provide powerful tools to increase our 
understanding of the genome in transplant outcomes (Werner, 
2010). For example, gene-expression studies microarrays are now 
being replaced by seq-based methods, which can identify and quan-
tify rare transcripts without prior knowledge of a particular gene and 
can provide information regarding alternative splicing and sequence 
variation in identified genes (Ozsolak and Milos, 2011).
Rethinking global approaches to studying kidney transplantation 
involves redefining the analyzed biological target. Clearly, proteins 
are more closely linked to biological function, and integrated views 
of the proteome will potentially provide a more precise picture of tis-
sue responses to injury. Recent technological progress in proteomics 
renders this approach attractive for fundamental scientific research 
on transplantation and also for molecular diagnosis. Nanoscale pro-
teomics (Saba et al., 2009), subcellular and organelle proteomics 
(Boulais et al., 2010), proteomics of post-translational modifica-
tions, phosphorylation (Eyrich et al., 2011), the immunopeptidome 
(de Verteuil et al., 2010), and the antibodiome (Li et al., 2009) are 
examples of powerful technologies that could transform our under-
standing of kidney allografts as biologically integrated systems.
The tremendous progress in proteomic technology, particu-
larly in mass spectrometry instrumentation, allowed proteomics 
to emerge as a powerful tool for biomarker research (Findeisen and 
methodology
Cultured cells are the simplest system for interpreting transcrip-
tomic analysis because each transcript comes from the same cell 
lineage. However, this system is oversimplified because it lacks inter-
actions with the surrounding microenvironment and intercellular 
communications. Furthermore, even in the case of a monotype cell 
culture system with a minimal number of interfering variables, 
reproducibility between experiments can be challenging. Such a 
simple model gives rise to complex and speculative interpreta-
tions about the consequences of the expression of the transcript 
of interest.
Conversely, transcriptomic analyses based on tissue extracts, 
such as kidney biopsies, integrate the transcript expression levels 
from many cell types, such as epithelial cells, endothelial cells, fibro-
blasts, and macrophages. It is clear that the transcripts present in a 
kidney biopsy are not produced uniformly by the organ as a whole 
but are a product of the cells within. As a result, the level of expres-
sion of the transcript τ represents the mean of all the expression 
levels (positive or negative) of τ in all cell types present in the biopsy. 
Thus, transcriptomic analysis of tissues reduces a multidimensional 
system (i.e., a multicellular and multicompartmental system) into 
an oversimplified, one-dimensional system with a tremendous loss 
of information (Shen-Orr et al., 2010). Because the expression level 
of a transcript integrates all cell types, it is difficult to ascertain 
whether its overexpression is a consequence of activation or of the 
accumulation of a particular cell type.
Overcoming these limitations remains a complicated task. 
Because the focal nature of structural alterations are common in 
the renal parenchyma in many human diseases and animal models, 
experimental methods for isolating subsets of tissues, such as cell 
sorting, enrichment, or the use of laser capture microdissected 
material, could be useful. However, these methods are prohibi-
tively expensive and may affect cell physiology and gene- expression. 
Interestingly, flow cytometry and cell sorting can be employed for 
sorting nuclei form cells, that could allow to distinguish diver-
gent cell populations within single biopsies that could help guide 
diagnoses and tailor approaches to personalized treatment (Ruiz 
et al., 2011). One solution could be the use of algorithms, such as 
cell-type specific significance analysis of microarrays (csSAM), that 
address the extensive loss of biological information in microarray 
datasets when analyzing complex tissue samples that vary in cellular 
composition. Such method can retrieve the information lost dur-
ing microarray processing and lead to the discovery of significant 
genes that were otherwise undetectable (Shen-Orr et al., 2010).
rethinking transcriptomic analysis in 
transplantation
The tremendous success of transcriptomic analysis has relied on 
the relative simplicity of using the platforms, the small amounts 
of biological materials required, and the hope of discovering bio-
logical phenomena that were previously unknown. Moreover, 
sophisticated bioinformatics tools render the use of microarrays 
even simpler and more impressive by producing unsupervised 
hierarchical clusters, which can elucidate a previously unidentified 
molecular reality. These comprehensive analysis tools have been 
attractive because they may have generated the hope of revealing 
many mechanisms of transplant-related diseases without having 
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conclusion
The arrival of “omics” in translational medicine, including 
transplant medicine, generated a conceptual twist in the for-
mulation of scientific problems and the methods available to 
solve them. The classical approach is based on the formation 
of a hypothesis, followed by the search for an adequate model 
to test it through planned experiments that are performed step 
by step. The power of the new biotechnological tools, however, 
has led to an inversion of this process; the tool is first used to 
generate data, the data is interpreted, and finally a hypothesis is 
formulated. This is another way of doing science, and although 
it is a powerful and effective one, it should not overshadow its 
own limitations. A critical interpretation of gene profiling studies 
is always necessary.
Neumaier, 2009). One advantage of proteomics is that it may analy-
sis all the proteins in any defined biologic compartment, including 
urine, in a non-invasive manner. Whereas mRNAs can be isolated 
from urine (Muthukumar et al., 2005), the collection of adequate 
quality, and quantity material remains challenging. Proteomics may 
complements transcriptomic approaches because the proteome is 
the result of alternative splicing of primary transcripts, the presence 
of sequence polymorphisms, and post-translational modifications, 
which are not monitored by transcriptomic analyses. Additionally, 
there is no strict linear relationship between the genome and the 
proteome and often a poor correlation between mRNA abundance 
in a cell or tissue and the quantity of the corresponding functional 
protein. However, this may represents a challenging task as pro-
teomes have a large and unknown complexity.
Before proteomics emerges as a reliable clinical diagnostic 
tool, some hurdles will have to be crossed, like the inconsistency 
in sample handling and processing and the lack of standardiza-
tion of experimental design. Furthermore, robust study design 
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